Corcept Therapeutics CORT Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$164.9M+4.9%

Gross profit$162.0M+4.7%

Operating income-$49.6M-1,552%

Net income-$31.8M-255%

EPS (diluted)-$0.30-276%

Balance sheet

See full

Cash & equivalents$110.0M+21.1%

Total debt$9.6M+41.0%

Total equity$638.0M-6.6%

Total assets$814.9M-3.7%

Cash flow

See full

Operating cash flow-$16.8M-452%

CapEx$201.0K+93.3%

Free cash flow-$17.0M-464%

Valuation

See full

Market cap$8.58B-64.4%

Enterprise value$8.48B-65.0%

P/E181.2×+1.3×

P/S11.2×-24.0×

Profitability

See full

Gross margin98.3%-0.2pp

Operating margin-1.1%-17.2pp

Net margin6.2%-13.4pp

FCF margin15.6%-10.2pp

Returns & leverage

See full

Return on equity7.2%-14.6pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corcept Therapeutics's payments for repurchase of common stock?: Corcept Therapeutics (CORT) reported payments for repurchase of common stock of $0 in Q1 2026.
How has Corcept Therapeutics's payments for repurchase of common stock changed year-over-year?: Corcept Therapeutics's payments for repurchase of common stock decreased by 100.0% year-over-year, from $27.43M to $0.